Undoubtedly, after years of neglect, bronchiectasis has become a focus of respiratory research, largely thanks to the establishment of various bronchiectasis registries. Baseline data from registries ...

Dr. Andy Whittamore, a GP and clinical lead at Asthma and Lung UK, shed light on four chronic lung conditions that tend to ...

The Company continues to anticipate that the totality of its early-stage research programs will comprise less than 20% of overall expenditure.

Insmed (INSM) reported preliminary 2024 revenue results for its drug Arikayce and issued 2025 revenue guidance. Read more ...

Drug maker Insmed (INSM) is rising 6% today after it released on Friday afternoon its estimate of the revenue generated by ...

Permanent changes such as bronchiectasis may persist. ABPA: Allergic bronchopulmonary aspergillosis; GINA: Global initiative for asthma. Adapted with permission from [7]. ABPA-S Fulfils the ...

In May 2024, management reported positive top-line results from the late-stage ASPEN study, which evaluated brensocatib in patients with bronchiectasis. Treatment with the drug achieved ...

Goldman Sachs has flagged Insmed Inc. as a potential merger candidate under the pro-business policies of the incoming Donald ...

inhaled multi-phage therapeutic for the treatment of chronic pulmonary Pseudomonas aeruginosa – P.a. or P. aeruginosa – infections in non-cystic fibrosis bronchiectasis, or NCFB, patients.

The success in the bronchiectasis market can offer the company ... Insmed has one commercially approved treatment for lung infections that is under review for expanded use. Recently another ...

For individuals with chronic lung conditions, the winter season and the current cold snap poses significant challenges.